Agreement - September 2, 2015
AstraZeneca in license agreement with Daiichi Sankyo
AstraZeneca’s global biologics research and development arm, MedImmune, has entered an agreement with Daiichi Sankyo. The agreement grants the company an exclusive license to develop and commercialise FluMist Quadrivalent in Japan. FluMist Quadrivalent is a live attenuated influenza vaccine which is administered as a nasal spray and contains four protective strains. Phase III safety and efficacy […]
Agreement - September 1, 2015
Recipharm in agreement with LobSor Pharmaceuticals
The Swedish CDMO Recipharm reaches agreement with LobSor Pharmaceuticals to manufacture LECIGONTM, a proprietary treatment for advanced Parkinson’s disease. Recipharm and LobSor Pharmaceuticals, an Uppsala-based pharmaceutical company focusing on the development of innovative systems to treat symptoms of advanced Parkinson’s disease (APD), has agreed on a manufacturing agreement for LECIGON. As part of the agreement, […]
Agreement - July 7, 2015
Heptares and AstraZeneca sign agreement
Heptares Therapeutics, a clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking […]
Agreement - July 2, 2015
Targovax, Oncos Strike Deal
Norwegian Targovax has entered an agreement with the shareholders of Finnish clinical-stage biotechnology company Oncos Therapeutics to acquire the shares of Oncos with settlement in Targovax shares. After the transaction, the shareholders of Oncos will own 50 per cent of Targovax. The new company already has received indications of interest from leading institutional investors, including a 26 […]
Agreement - June 28, 2015
Sobi Dismisses Takeover Talk
Sobi’s board of directors has ended any discussions about the possible sale of all shares issued by the company. “Sobi will continue to focus on preparations for the upcoming planned launch of Elocta and Alprolix and on building value through its diverse and growing portfolio,” the company said in a statement. Sobi had a market value […]
Agreement - May 28, 2015
CEO: No Interest in Selling Firm
Despite Bavarian Nordic’s recent successes forging deals with major companies and attractiveness to larger firms, there are no plans to sell the company, says CEO Paul Chaplin in a FierceBiotech article. “You can’t stop interest if there is interest, but it’s not our ambition to sell the company,” Chaplin told Reuters. “Our end goal is not to sell to Big Pharma as […]
